Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Albemarle Corp. (ALB) vs Novavax Inc (NVAX) Price & Performance

Albemarle Corp.Trade
Novavax IncTrade

Price performance (Past 24H)

Key statistics

Albemarle Corp. vs Novavax Inc — how do they compare? Albemarle Corp. trades at $129.13 (market cap $15.27B), while Novavax Inc trades at $7.94 (market cap $1.31B). The key difference: Albemarle Corp. is far larger — about 11.7× Novavax Inc's market cap, and Albemarle Corp. pays a 1.27% dividend while Novavax Inc pays none. Which is the better fit depends on your goals.

ALBNVAX
Market Cap
$15.27B$1.31B
Sector
Basic MaterialsHealth
52-Week High
$215.62$11.19
52-Week Low
$72.58$6.22
Enterprise Value
$17.75B$889.30M
Dividend Yield
1.27%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Albemarle Corp.

Albemarle (ALB) trades at $131.21, up 0.08% on the day, showing a bullish technical trend with strong support at $129 and resistance at $133. The company reported robust Q2 2026 results, beating EPS estimates with $3.75 versus $3.20 expected, driven by improved lithium pricing and specialties growth. However, net income remains negative for 2025 at -$510.63M, and the P/E ratio is elevated at 479.11, indicating high valuation expectations. Analyst sentiment is mixed with a consensus price target of $184.50 but only 42% buy ratings.

Outlook: ALB benefits from strong lithium demand and cost controls, but faces risks from volatile lithium prices and sequential margin pressure in Q3. The stock offers growth potential if execution continues, yet high valuation and earnings inconsistency warrant caution. Near-term price action hinges on Q3 results and lithium market trends.

Novavax Inc

Novavax (NVAX) trades at $7.97, up 1.01% with a mixed technical picture showing bullish overall signals but bearish moving averages. The company reported strong Q2 2026 results, beating revenue and earnings estimates while raising full-year guidance. Despite negative profitability metrics, valuation ratios appear attractive with P/E of 3.14 and EV/EBITDA of 1.72. Recent news highlights progress with Sanofi partnership and cost reduction initiatives.

The outlook remains challenged by negative cash flows and accumulated deficits, but analyst sentiment is positive with 74% buy ratings. Key risks include ongoing operational losses and vaccine demand volatility, while potential upside exists from partnership milestones and adjuvant platform expansion. The stock presents a high-risk opportunity with significant analyst support despite fundamental weaknesses.

Returns comparison

Trailing returns across standard periods

About Albemarle Corp.

Albemarle is the world's largest lithium producer. Our outlook for robust lithium demand is predicated upon increased demand for electric vehicle batteries. Albemarle produces lithium from its salt brine deposits in Chile and the U.S. and its hard rock joint venture mines in Australia. Albemarle is also a global leader in the production of bromine, used in flame retardants. The company is also a major producer of oil refining catalysts.

Read more on ALB

About Novavax Inc

Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.

Read more on NVAX